JP2019524836A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524836A5 JP2019524836A5 JP2019508963A JP2019508963A JP2019524836A5 JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5 JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019508963 A JP2019508963 A JP 2019508963A JP 2019524836 A5 JP2019524836 A5 JP 2019524836A5
- Authority
- JP
- Japan
- Prior art keywords
- unit dosage
- dosage form
- active agent
- therapeutically active
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims 27
- 239000013543 active substance Substances 0.000 claims 16
- 238000010521 absorption reaction Methods 0.000 claims 12
- 239000003623 enhancer Substances 0.000 claims 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims 5
- 108090000445 Parathyroid hormone Proteins 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 239000000199 parathyroid hormone Substances 0.000 claims 5
- 229960001319 parathyroid hormone Drugs 0.000 claims 5
- UQFYDAAKCZKDHS-UHFFFAOYSA-M sodium;4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound [Na+].OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O UQFYDAAKCZKDHS-UHFFFAOYSA-M 0.000 claims 5
- XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 claims 4
- 238000004503 metal oxide affinity chromatography Methods 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- AKVBCGQVQXPRLD-UHFFFAOYSA-N 2-aminooctanoic acid Chemical compound CCCCCCC(N)C(O)=O AKVBCGQVQXPRLD-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 231100001126 band 3 compound Toxicity 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 claims 1
- 229940124532 absorption promoter Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- -1 hydroxy-4-chlorobenzoyl Chemical group 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022099609A JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662375989P | 2016-08-17 | 2016-08-17 | |
| US62/375,989 | 2016-08-17 | ||
| PCT/IL2017/050920 WO2018033927A1 (en) | 2016-08-17 | 2017-08-17 | Formulations for oral administration of active agents |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099609A Division JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Division JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524836A JP2019524836A (ja) | 2019-09-05 |
| JP2019524836A5 true JP2019524836A5 (enExample) | 2020-09-17 |
| JP7530173B2 JP7530173B2 (ja) | 2024-08-07 |
Family
ID=61196521
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508963A Active JP7530173B2 (ja) | 2016-08-17 | 2017-08-17 | 活性薬剤の経口投与のための製剤 |
| JP2022099609A Active JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Active JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A Pending JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022099609A Active JP7546622B2 (ja) | 2016-08-17 | 2022-06-21 | 活性薬剤の経口投与のための製剤 |
| JP2024016436A Active JP7736834B2 (ja) | 2016-08-17 | 2024-02-06 | 活性薬剤の経口投与のための製剤 |
| JP2025076671A Pending JP2025114692A (ja) | 2016-08-17 | 2025-05-02 | 活性薬剤の経口投与のための製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12239691B2 (enExample) |
| EP (1) | EP3500291A4 (enExample) |
| JP (4) | JP7530173B2 (enExample) |
| KR (4) | KR20230088854A (enExample) |
| CN (4) | CN116831978A (enExample) |
| AU (2) | AU2017311698B2 (enExample) |
| BR (1) | BR112019003136A2 (enExample) |
| CA (1) | CA3033259A1 (enExample) |
| IL (3) | IL264880B2 (enExample) |
| MX (1) | MX2019001850A (enExample) |
| NZ (1) | NZ751668A (enExample) |
| SG (1) | SG11201901070YA (enExample) |
| WO (1) | WO2018033927A1 (enExample) |
| ZA (1) | ZA201901370B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6925969B2 (ja) | 2015-02-09 | 2021-08-25 | エンテラ バイオ エルティーディー． | 医薬組成物 |
| SG11201901070YA (en) | 2016-08-17 | 2019-03-28 | Entera Bio Ltd | Formulations for oral administration of active agents |
| UY38480A (es) * | 2018-11-19 | 2020-06-30 | Receptor Holdings Inc | Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides |
| CN118873509A (zh) * | 2020-03-18 | 2024-11-01 | 西藏海思科制药有限公司 | 口服药物组合物 |
| WO2023161936A1 (en) * | 2022-02-24 | 2023-08-31 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone |
| MX2024010387A (es) * | 2022-02-24 | 2024-09-04 | Entera Bio Ltd | Formulaciones que comprenden polimero neutralizante de acido para administracion oral de agentes activos. |
| US20250186559A1 (en) * | 2022-02-24 | 2025-06-12 | Entera Bio Ltd. | Formulations comprising acid-neutralizing polymer for oral administration of parathyroid hormone |
| WO2025046589A1 (en) * | 2023-08-30 | 2025-03-06 | Entera Bio Ltd. | Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5360793A (en) | 1993-05-24 | 1994-11-01 | Sterling Winthrop Inc. | Rafting antacid formulation |
| US6984728B2 (en) | 1993-09-24 | 2006-01-10 | Schering Corporation | Recombinant infectious laryngotracheitis virus and uses thereof |
| CN1162917A (zh) | 1994-10-07 | 1997-10-22 | 伯温德药品服务公司 | 肠内涂层组合物，用其涂覆的方法和涂覆制品 |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| CA2220301C (en) | 1995-06-02 | 2006-02-21 | Alza Corporation | Osmotic device with delayed activation of drug delivery and complete drug release |
| JP3880093B2 (ja) | 1995-08-08 | 2007-02-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 錠剤 |
| JP3220373B2 (ja) | 1995-11-28 | 2001-10-22 | バイエル薬品株式会社 | 持続性ニフエジピン製剤 |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| CN1228708A (zh) | 1996-09-04 | 1999-09-15 | 有限会社多特 | 经口给药用含肽药物组合物 |
| US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
| WO2000048589A1 (en) | 1999-02-22 | 2000-08-24 | Emisphere Holdings, Inc. | Solid oral dosage form containing heparin or a heparinoid in combination with a carrier |
| WO2000050386A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| NZ534409A (en) | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
| HK1048801B (en) | 1999-11-05 | 2009-08-28 | Emisphere Technologies, Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| AU1594801A (en) | 1999-11-12 | 2001-06-06 | Emisphere Technologies, Inc. | Liquid heparin formulation |
| MXPA04001418A (es) | 2001-08-17 | 2004-05-27 | Novartis Ag | Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides. |
| JP4602668B2 (ja) | 2001-11-13 | 2010-12-22 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するためのフェノキシアミン化合物および組成物 |
| JP5196701B2 (ja) | 2001-11-29 | 2013-05-15 | エミスフィアー テクノロジーズ インコーポレイテッド | クロモリンナトリウムの経口投与用製剤 |
| JP4417110B2 (ja) * | 2001-12-19 | 2010-02-17 | 株式会社三和化学研究所 | 放出制御型成型品 |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US20050054557A1 (en) | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| AR040737A1 (es) | 2002-08-01 | 2005-04-20 | Novartis Ag | Administracion oral de calcitonina |
| CA2531136A1 (en) | 2003-07-04 | 2005-01-13 | Nycomed Danmark Aps | Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| JP2005281231A (ja) | 2004-03-30 | 2005-10-13 | Bioserentack Co Ltd | 小腸ターゲットタイプの経口ｄｄｓ製剤 |
| US20060052306A1 (en) | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| JP2006111558A (ja) | 2004-10-14 | 2006-04-27 | Bioserentack Co Ltd | 多層構造を有する錠剤状の小腸粘膜付着性経口製剤 |
| NZ555244A (en) * | 2004-11-19 | 2010-06-25 | Smithkline Beecham Corp | Manufacture process for pharmaceutical product allowing delivery of a plurality of active agents |
| US8110547B2 (en) * | 2005-01-12 | 2012-02-07 | Emisphere Technologies, Inc. | Compositions for buccal delivery of parathyroid hormone |
| US20080153779A1 (en) * | 2005-02-01 | 2008-06-26 | Jun Liao | Gastric Retention and Controlled Release Delivery System |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| JP5123471B2 (ja) | 2005-08-18 | 2013-01-23 | 帝人ファーマ株式会社 | 用量調整が容易な製剤 |
| AU2006288703B2 (en) | 2005-09-06 | 2011-09-22 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
| US7629331B2 (en) | 2005-10-26 | 2009-12-08 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof |
| CN101309674A (zh) * | 2005-11-17 | 2008-11-19 | 诺瓦提斯公司 | 药物组合物 |
| US20070178155A1 (en) | 2006-01-31 | 2007-08-02 | Jiang David Yihai | Preparation for gastric buoyant sustained drug release dosage form |
| WO2007117706A2 (en) * | 2006-04-07 | 2007-10-18 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US8927015B2 (en) * | 2006-04-12 | 2015-01-06 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2007372B1 (en) | 2006-04-18 | 2015-03-04 | Emisphere Technologies, Inc. | Dialkyl ether delivery agents |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| WO2008132727A2 (en) | 2007-04-26 | 2008-11-06 | Technion Research And Development Foundation Ltd | Oral delivery of proteins and peptides |
| EP2200592A2 (en) | 2007-09-11 | 2010-06-30 | Orahealth Corporation | Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach |
| WO2009080764A2 (en) | 2007-12-20 | 2009-07-02 | Abylnx N.V. | Oral or nasal administration of compounds comprising amino acid sequences |
| IT1393244B1 (it) * | 2008-07-18 | 2012-04-12 | Universita' Degli Studi Di Milano | Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale |
| JP5740689B2 (ja) * | 2008-08-18 | 2015-06-24 | エンテラ バイオ エルティーディー． | タンパク質の経口投与用の方法および組成物 |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| BR112012026098A2 (pt) | 2010-04-16 | 2016-11-22 | Novartis Ag | métodos e composições para melhorar a osseointegração de implante. |
| PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| US20130224300A1 (en) | 2011-08-26 | 2013-08-29 | Edward T. Maggio | Compositions and methods thereof for oral administration of drugs |
| WO2013067309A1 (en) | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
| JP6517690B2 (ja) * | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| US9803731B2 (en) | 2014-04-24 | 2017-10-31 | American Axle & Manufacturing, Inc. | Actuator device having cam and follower and controller configured to employ rate-based methodology to identify positioning of follower on cam at predetermined location |
| EP2975118B1 (en) | 2014-07-16 | 2016-08-24 | Johann Wolfgang Goethe-Universität, Frankfurt am Main | Generation of a mesenchymal stromal cell bank from the pooled mononuclear cells of multiple bone marrow donors |
| JP6925969B2 (ja) | 2015-02-09 | 2021-08-25 | エンテラ バイオ エルティーディー． | 医薬組成物 |
| SG11201901070YA (en) | 2016-08-17 | 2019-03-28 | Entera Bio Ltd | Formulations for oral administration of active agents |
| JP7419862B2 (ja) | 2020-02-14 | 2024-01-23 | 株式会社リコー | 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置 |
-
2017
- 2017-08-17 SG SG11201901070YA patent/SG11201901070YA/en unknown
- 2017-08-17 JP JP2019508963A patent/JP7530173B2/ja active Active
- 2017-08-17 KR KR1020237019713A patent/KR20230088854A/ko not_active Ceased
- 2017-08-17 KR KR1020247029460A patent/KR102832566B1/ko active Active
- 2017-08-17 CN CN202311014662.XA patent/CN116831978A/zh active Pending
- 2017-08-17 WO PCT/IL2017/050920 patent/WO2018033927A1/en not_active Ceased
- 2017-08-17 IL IL264880A patent/IL264880B2/en unknown
- 2017-08-17 CN CN201780064008.6A patent/CN109862906A/zh active Pending
- 2017-08-17 MX MX2019001850A patent/MX2019001850A/es unknown
- 2017-08-17 US US16/326,213 patent/US12239691B2/en active Active
- 2017-08-17 NZ NZ751668A patent/NZ751668A/en unknown
- 2017-08-17 CN CN202311014654.5A patent/CN116831977A/zh active Pending
- 2017-08-17 IL IL312218A patent/IL312218B2/en unknown
- 2017-08-17 KR KR1020247016245A patent/KR102832565B1/ko active Active
- 2017-08-17 AU AU2017311698A patent/AU2017311698B2/en active Active
- 2017-08-17 IL IL321113A patent/IL321113A/en unknown
- 2017-08-17 KR KR1020197007250A patent/KR20190039768A/ko not_active Ceased
- 2017-08-17 CN CN202311018541.2A patent/CN116850132A/zh active Pending
- 2017-08-17 BR BR112019003136A patent/BR112019003136A2/pt unknown
- 2017-08-17 CA CA3033259A patent/CA3033259A1/en active Pending
- 2017-08-17 EP EP17841226.8A patent/EP3500291A4/en active Pending
-
2019
- 2019-03-05 ZA ZA2019/01370A patent/ZA201901370B/en unknown
-
2022
- 2022-06-21 JP JP2022099609A patent/JP7546622B2/ja active Active
-
2024
- 2024-02-06 JP JP2024016436A patent/JP7736834B2/ja active Active
- 2024-08-20 AU AU2024211004A patent/AU2024211004B2/en active Active
- 2024-08-29 US US18/818,691 patent/US20240415936A1/en active Pending
-
2025
- 2025-05-02 JP JP2025076671A patent/JP2025114692A/ja active Pending